

ML-IAP (4H196): sc-71592

BACKGROUND

Inhibitor of apoptosis proteins (IAPs) contain conserved, unique N-terminal baculovirus IAP repeats (BIRs) and usually a C-terminal RING finger domain. Immunoprecipitation and Western blot analysis indicate that ML-IAP, also known as melanoma inhibitor of apoptosis protein, kidney inhibitor of apoptosis protein (KIAP), livin or BIRC7, binds to caspase-3, -7 and -9, but only inhibits caspase-9. Additionally, ML-IAP physically interacts with Smac through its BIR domain with a very high affinity and this interaction is very specific. The gene which encodes ML-IAP maps to human chromosome 20q13.33. There is controversy regarding the localization of this protein and its involvement in apoptosis, but it has been suggested that ML-IAP may play a complex role in the regulation of apoptosis.

REFERENCES

- Vucic, D., et al. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr. Biol.* 10: 1359-1366.
- Lin, J.H., et al. 2000. KIAP, a novel member of the inhibitor of apoptosis protein family. *Biochem. Biophys. Res. Commun.* 279: 820-831.
- Kasof, G.M., et al. 2001. Livin, a novel inhibitor of apoptosis protein family member. *J. Biol. Chem.* 276: 3238-3246.
- Ashhab, Y., et al. 2001. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. *FEBS Letts.* 495: 56-60.
- Online Mendelian Inheritance in Man, OMIM™. 2001. Johns Hopkins University, Baltimore, MD. MIM Number: 605737. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
- Vucic, D., et al. 2002. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). *J. Biol. Chem.* 277: 12275-12279.
- Franklin, M.C., et al. 2003. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). *Biochemistry* 42: 8223-8231.
- Andersen, M.H., et al. 2004. Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. *J. Invest. Dermatol.* 122: 1336-1337.
- Vucic, D., et al. 2004. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. *Biochem. J.* 385: 11-20.

CHROMOSOMAL LOCATION

Genetic locus: BIRC7 (human) mapping to 20q13.33.

SOURCE

ML-IAP (4H196) is a mouse monoclonal antibody raised against ML-IAP of human origin.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 100 µg IgG₁ in 1.0 ml PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

ML-IAP (4H196) is recommended for detection of ML-IAP of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)].


Suitable for use as control antibody for ML-IAP siRNA (h): sc-37510, ML-IAP shRNA Plasmid (h): sc-37510-SH and ML-IAP shRNA (h) Lentiviral Particles: sc-37510-V.

Molecular Weight of full length ML-IAP: 40 kDa.


Molecular Weight of ML-IAP cleavage fragment: 30 kDa.

Positive Controls: SK-MEL-28 cell lysate: sc-2236 or ML-IAP (h): 293T Lysate: sc-159337.

DATA



ML-IAP (4H196): sc-71592. Western blot analysis of ML-IAP expression in SK-MEL-28 whole cell lysate.



ML-IAP (4H196): sc-71592. Western blot analysis of ML-IAP expression in non-transfected: sc-117752 (A) and human ML-IAP transfected: sc-159337 (B) 293T whole cell lysates.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.